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Abstract
Introduction: Lactic acidosis can develop during biguanide (metformin and phenformin) intoxication, possibly as a 
consequence of mitochondrial dysfunction. To verify this hypothesis, we investigated whether body oxygen 
consumption (VO2), that primarily depends on mitochondrial respiration, is depressed in patients with biguanide 
intoxication.
Methods: Multicentre retrospective analysis of data collected from 24 patients with lactic acidosis (pH 6.93 ± 0.20; 
lactate 18 ± 6 mM at hospital admission) due to metformin (n = 23) or phenformin (n = 1) intoxication. In 11 patients, 
VO2 was computed as the product of simultaneously recorded arterio-venous difference in O2 content [C(a-v)O2] and 
cardiac index (CI). In 13 additional cases, C(a-v)O2, but not CI, was available.
Results: On day 1, VO2 was markedly depressed (67 ± 28 ml/min/m2) despite a normal CI (3.4 ± 1.2 L/min/m2). C(a-v)O2 
was abnormally low in both patients either with (2.0 ± 1.0 ml O2/100 ml) or without (2.5 ± 1.1 ml O2/100 ml) CI (and 
VO2) monitoring. Clearance of the accumulated drug was associated with the resolution of lactic acidosis and a parallel 
increase in VO2 (P < 0.001) and C(a-v)O2 (P < 0.05). Plasma lactate and VO2 were inversely correlated (R2 0.43; P < 0.001, n 
= 32).
Conclusions: VO2 is abnormally low in patients with lactic acidosis due to biguanide intoxication. This finding is in line 
with the hypothesis of inhibited mitochondrial respiration and consequent hyperlactatemia.
Introduction
Metformin and phenformin are oral anti-diabetic drugs of
the biguanide class. Metformin is the first-line drug of
choice for the treatment of adults with type 2 diabetes [1]. It
is the 10th most frequently prescribed generic drug in the
USA (>40 million prescriptions in 2008) and is currently
used by almost one-third of diabetic patients in Italy [2,3].
Phenformin is no longer on sale in many countries, but is
still available in Italy.
Lactic acidosis can develop in patients taking metformin
or phenformin, especially when renal failure leads to drug
accumulation [4-6]. According to the American Association
of Poison Control Centers, metformin was implicated in 19
fatalities in the USA in 2007 [7]. Thirty cases of biguanide
intoxication have been reported over the past two years to
the Poison Control Centre of Pavia, Italy, resulting in 10
deaths (Dr Sarah Vecchio, unpublished data). The progres-
sive increase in metformin use (20% rise in prescriptions
between 2006 and 2008 in the USA) may result in a parallel
increase in the incidence of associated lactic acidosis [2,8].
The pathogenesis of biguanide-associated lactic acidosis
remains unclear, especially when it develops in the absence
of other major risk factors such as hypoxia, tissue hypoper-
fusion, or liver failure (biguanide-induced lactic acidosis).
Hyperlactatemia is classically attributed to an impaired lac-
tate clearance, secondary to an exaggerated inhibition of
hepatic gluconeogenesis [9] but may also depend on an
increased lactate production by the liver [10] or the intes-
tine [11].
Biguanide drugs mainly exert their therapeutic effect by
impairing hepatocyte mitochondrial respiration [12,13].
Recent observations have suggested that metformin, simi-
larly to phenformin, might also inhibit mitochondrial respi-
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Page 2 of 9ration in tissues other than the liver [14-16]. Mitochondria
produce energy while consuming oxygen (O2) and releasing
carbon dioxide (CO2) and heat. When O2 provision or utili-
zation are compromised, cellular energy production can
partly rely on the extra-mitochondrial anaerobic lactate
generation, that is associated with metabolic acidosis. As
mitochondrial respiration normally accounts for more than
90% of whole body O2 utilization and CO2 release, any
defect in mitochondrial metabolism will decrease systemic
O2 consumption and CO2 production.
We hypothesize that inhibition of mitochondrial respira-
tion is responsible for the development of lactic acidosis
during metformin or phenformin intoxication. If our
hypothesis is correct, respiration should be abnormally low
regardless of any change in systemic O2 delivery. The aim
of this study is to investigate global O2 consumption (and
CO2 production) in patients with lactic acidosis due to bigu-
anide intoxication.
Materials and methods
We reviewed the data sheets of patients admitted to 12
intensive care units and 1 nephrology unit of 11 hospitals
from January 2005 to June 2009, with a discharge diagnosis
of lactic acidosis due to biguanide intoxication. Patients
with a concomitant primary diagnosis of septic or cardio-
genic shock or liver failure were excluded. Lactic acidosis
was defined as pH less than 7.30 and plasma lactate more
than 5 mM. Only patients with central or mixed venous O2
saturation monitoring were included.
We calculated the arterio-venous difference in O2 content
[C(a-v)O2] as:
where CaO2 and CvO2 are arterial and venous blood O2
content, respectively, Hb is blood hemoglobin concentra-
tion, SaO2 is arterial O2 saturation, SvO2 is O2 saturation of
blood taken from the superior vena cava or the pulmonary
artery (collectively indicated as central venous blood) and
PaO2 and PvO2 are the arterial and central venous O2 ten-
sions.
Oxygen extraction index (OEI) was defined as:
and expressed as a percentage. The veno-arterial differ-
ence in CO2 content [C(v-a)CO2] was calculated according
to Douglas and colleagues [17]. In patients with cardiac
index (CI) monitoring, we calculated whole body O2 deliv-
ery (DO2) as CI × CaO2 and O2 consumption (VO2) as CI ×
C(a-v)O2, with CI computed as cardiac output divided by
estimated body surface area. Carbon dioxide production
(VCO2) was calculated as CI × C(v-a)CO2.
The severity of illness was initially expressed by the Sim-
plified Acute Physiology Score (SAPS) II [18] and then
monitored using the Sequential Organ Failure Assessment
(SOFA) score [19]. The cardiovascular SOFA score was
used to describe catecholamine requirements. Sedation was
evaluated using the Richmond Agitation Sedation Scale
(RASS) [20]. Heart rate, body temperature and need for
mechanical ventilation were also recorded. Analysis was
restricted to the first four days following admission, or until
discharge or death if any of these occurred earlier.
The local Ethics Committee of the coordinating Centre
(Fondazione IRCCS Ospedale Maggiore Policlinico, Man-
giagalli e Regina Elena di Milano, Italy) was informed of
the ongoing retrospective analysis and did not require any
specific informed consent.
Statistical analysis
Results are presented as mean ± standard deviation or
median and interquartile range, based on data distribution
(Kolmogorov-Smirnov test). The relation between serum
metformin levels and other variables was assessed using
linear regression analysis and expressed as R2. Severity of
illness at admission of patients with or without CI monitor-
ing was compared using the Student's t-test. The remainder
of the analyses were performed on data averaged on a daily
basis. Changes occurring over time were investigated using
parametric or non-parametric one-way repeated-measures
analysis of variance. Post-hoc comparisons were performed
using Bonferroni or Dunn's test, considering day 1 as base-
line. The relation between the arterio-venous difference in
O2 content and the veno-arterial difference in CO2 content
was calculated using linear regression. The relation
between systemic O2 consumption and other variables was
investigated using linear (arterial pH) or non-linear (body
temperature and plasma lactate) regression. The chi-
squared test was used to assess whether the proportion of
patients requiring mechanical ventilation changed over
time. Analysis was performed using Sigma Stat version
3.1.1 (Jandel Scientific Software; San Jose, CA, USA). A
two-sided P value less than 0.05 was considered as statisti-
cally significant.
Results
We identified 24 diabetic patients admitted to the intensive
care (n = 22) or nephrology (n = 2) units with lactic acidosis
attributed to either metformin (n = 23) or phenformin (n =
1) intoxication (Table 1). Seventeen (71%) were females
and the mean age of all patients was 66 ± 9 years.
Lactic acidosis on hospital admission was always severe,
with an arterial pH of 6.93 ± 0.20 and lactate of 18 ± 6 mM.
Blood glucose level was 118 ± 78 mg/dl, with severe hypo-
glycemia (<40 mg/dl) being present in 3 patients. Liver
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Page 3 of 9Table 1: Main characteristics of the study population
Id Intoxicant Serum 
drug level 
(μg/ml)
Creatinine 
(mg/dl)
pH Lactate 
(mM)
Monitoring SAPS II ICU 
outcome
1 Metformin 70 6.4 7.21 22
CI; 
58 S
2 Metformin 63 12.4 6.95 33
CI; 
53 S
3 Metformin NA 10.8 6.76 21
CI; 
61 S
4 Metformin NA 15.2 7.06 18
CI; 
51 S
5 Metformin NA 9.0 6.63 21
CI; 
55 S
6 Metformin NA 10.3 6.82 21 CI; ScvO2 87 S
7 Metformin NA 10.8 6.70 24 CI; ScvO2 74 S
8 Metformin 61 1.9 7.27 10
CI; 
83 NS
9 Metformin NA 13.2 6.79 21 CI; ScvO2 63 S
10 Metformin NA 4.7 7.13 19 CI; ScvO2 66 S
11 Metformin 53 4.5 <6.80 16
CI; 
87 NS
12 Metformin 65 8.4 6.76 22 ScvO2 43 S
13 Phenformin 480§ 9.5 6.91 13 ScvO2 59 S
14 Metformin 100 5.8 7.26 10 ScvO2 58 S
15 Metformin 63 4.2 6.89 18 ScvO2 53 NS
16 Metformin NA 13.0 6.93 17 ScvO2 67 S
17 Metformin 19† 9.9 6.62 19 ScvO2 62 S
18 Metformin NA 6.1 <6.80 24 ScvO2 70 NS
19 Metformin 100 7.6 6.87 16 ScvO2 45 S
20 Metformin 25† 9.3 6.81 15 ScvO2 44 S
21* Metformin 70 4.8 7.22 11 ScvO2 66 S
22* Metformin 44 10.0 6.93 14 ScvO2 55 S
23 Metformin NA 13.8 7.21 6 ScvO2 39 S
24 Metformin NA 7.1 6.93 17 ScvO2 65 NS
The first available serum drug concentration (§ phenformin in ng/ml;† blood sample obtained with ongoing renal replacement therapy), 
creatinine level, arterial blood pH and plasma lactate level, available data (CI, cardiac index; ScvO2, central venous oxymetry; , mixed 
venous oxymetry), severity of the disease (expressed as Simplified Acute Physiology Score (SAPS) II score) and outcome (S = survivor; NS = 
non survivor) are reported. Target values in patients on metformin or phenformin are less than 4 μg/ml and less than 140 ng/ml, respectively. 
ICU, intensive care unit; NA, not available; * patients admitted to the Nephrology Unit.
SvO 2
SvO 2
SvO 2
SvO 2
SvO 2
SvO 2
SvO 2
SvO 2
function tests were usually normal, with alanine amin-
otransferase 66 ± 78 IU/L, total bilirubin 0.4 ± 0.2 mg/dl,
albumin 33 ± 6 g/L, and prothrombin time (expressed as
international normalized ratio) 1.2 ± 0.3 (excluding two
patients on warfarin). Left ventricular ejection fraction,
investigated in seven patients by echocardiography, was
always normal (≥ 50%).
Intoxication was always accidental and associated with
renal failure (creatinine 8.7 ± 3.5 mg/dl, urea 171 ± 70 mg/
dl and oligo-anuria) and continued drug intake. Factors
potentially implicated in the development of renal failure
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or diarrhea was reported in 75% of the cases), urinary tract
infection (29%) and chronic renal dysfunction (21%).
Whenever measured, serum drug concentration on day 1
was always well above safe limits (metformin 61 ± 25 vs.
<4 μg/ml, n = 12; phenformin 480 vs. <140 ng/ml, n = 1).
Metformin levels, measured at different time points in 10
patients, were positively correlated with those of creatinine
(R2 = 0.34; P < 0.001, n = 29) and lactate (R2 = 0.49; P <
0.001, n = 29) and inversely correlated with arterial pH (R2
= 0.68; P < 0.001, n = 29).
Treatment included the use of mechanical ventilation (n =
16), catecholamines (n = 21) and renal replacement therapy
(n = 21). The first day SAPS II score was 61 ± 13, corre-
sponding to an expected mortality of approximately 70%.
Observed mortality was 21%.
Central venous O2 saturation was monitored through a
central venous (n = 17) or pulmonary artery (n = 7) catheter.
Blood gases were always measured at 37°C. In 11 patients,
CI was also measured, using the PiCCO system (n = 2),
transesophageal Doppler ultrasonography (n = 2) or pulmo-
nary artery catheter thermodilution (n = 7). Patients with CI
monitoring had a higher SAPS II (67 ± 14 vs. 56 ± 10; P <
0.05) and SOFA (12 ± 3 vs. 9 ± 2; P < 0.05) scores on
admission.
Main results are reported in Table 2 and Figures 1 and 2.
Systemic O2 consumption, monitored in 11 patients, was
abnormally low on day 1 and normalized within the next 48
to 72 hours (P < 0.001), paralleled by resolution of lactic
acidosis (P < 0.001). As systemic O2 delivery did not signif-
icantly change compared with day 1, variations in whole
body O2 consumption were reflected in equal changes in
Table 2: Temporal changes observed in 11 biguanide-intoxicated patients with cardiac index and central venous oxygen 
saturation monitoring
n Day 1 Day 2 Day 3 Day 4 P
pH 11 7.03
(6.92-7.15)
7.35
(7.25-7.40)
7.44
(7.35-7.46)*
7.46
(7.44-7.47)*
<0.001
Lactate (mM) 11 17 (14-20) 5 (2-15) 2 (2-3)* 1 (1-3)* <0.001
VO2 (ml/min/m2) 9 67 ± 28 99 ± 30* 116 ± 41* 129 ± 42* <0.001
DO2 (ml/min/m2) 9 443 ± 167 572 ± 152 491 ± 95 430 ± 116 <0.01
CI (L/min/m2) 9 3.4 ± 1.2 4.4 ± 1.3 3.9 ± 0.8 3.4 ± 1.2 0.08
C(a-v)O2
(ml O2/100 ml)
10 2.0 ± 1.0 2.4 ± 0.8 2.9 ± 0.8* 3.8 ± 1.4* <0.001
SvO2 (%) 10 83 ± 8 80 ± 6 75 ± 5* 70 ± 8* <0.001
OEI (%) 10 13 (11-19) 16 (13-21) 23 (21-25)* 31 (23-34)* <0.001
C(v-a)CO2
(ml CO2/100 ml)
7 2.2 ± 0.8 2.2 ± 0.8 3.9 ± 1.9 4.7 ± 1.2* <0.05
RASS 11 -4 (-5--2) -4 (-4--1) -2 (-4-0) -1 (-3-0) 0.06
On MV (%) 11 91 100 67 67 0.12
HR 11 103 ± 20 104 ± 8 99 ± 16 97 ± 21 0.74
SOFA 11 12 ± 3 10 ± 1* 9 ± 2* 10 ± 2* <0.001
Catecholamine 
use (SOFA sub 
score)
11 4 (4-4) 4 (4-4) 4 (4-4) 3 (2-3)* <0.001
BT (°C) 10 34.5 ± 2.2 36.6 ± 0.6* 36.8 ± 0.4* 36.7 ± 0.5* <0.001
Results of repeated-measures analysis of variance and chi-squared test are reported in the right column. Data significantly different from day 
1 on post-hoc comparison are indicated as *. n is the number of patients with each specific variable monitored on day 1.BT, body temperature; 
C(a-v)O2, arterio-venous difference in oxygen content; C(v-a)CO2, veno-arterial difference in carbon dioxide content; CI, cardiac index; DO2, 
systemic oxygen delivery; HR, heart rate; MV, mechanical ventilation; OEI, oxygen extraction index; RASS, Richmond Agitation Sedation Score; 
SOFA, Sequential Organ Failure Assessment; SvO2, central venous oxygen saturation; VO2, systemic oxygen consumption.
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index and opposite changes in central venous O2 saturation
(P < 0.001 for all). The difference in veno-arterial CO2 con-
tent was abnormally low on day 1 and progressively
returned to normal (P < 0.05). Whole body CO2 production
showed a similar, although not significant, trend, rising
from 93 ± 24 (on day 1) to 115 ± 13 ml/min/m2 (on day 4; n
= 4). The arterio-venous difference in O2 content was posi-
tively associated with the veno-arterial difference in CO2
content (R2 = 0.42; P = 0.001, n = 22). Systemic O2 con-
sumption was positively associated with arterial pH (R2 =
0.37; P < 0.001, n = 32) and body temperature (R2 = 0.38; P
< 0.001, n = 30) and inversely correlated with plasma lac-
tate (R2 = 0.43; P < 0.001, n = 32).
Major findings remained valid when the analysis was
restricted to the 7 patients monitored with a pulmonary
artery catheter. From day 1 to 4, lactate levels decreased
from 16 (13 to 19) to 1 (1 to 2) mM (P < 0.01). Global O2
consumption increased (81 ± 21 vs. 129 ± 47 ml/min/m2; P
= 0.01) despite no change in systemic O2 delivery (482 ±
180 vs. 441 ± 139 ml/min/m2; P = 0.10). The arterio-
venous difference in O2 content (2.3 ± 1.2 vs. 3.9 ± 1.1 ml
O2/100 ml; P = 0.001) and the O2 extraction index (17 ± 7
vs. 30 ± 6%; P < 0.001) augmented and the mixed venous
O2 saturation accordingly decreased (81 ± 9 vs. 69 ± 6%; P
= 0.001). The difference in veno-arterial CO2 content
increased from 2.4 ± 0.7 to 4.6 ± 1.5 ml CO2/100 ml (P <
0.05). Systemic O2 consumption inversely correlated with
plasma lactate (R2 = 0.30; P = 0.01, n = 21).
In patients without CI monitoring, initial values and later
changes in the other variables of interest closely resembled
those observed in monitored patients (Table 3).
Twelve patients had one or more simultaneous determina-
tions of serum metformin levels and arterio-venous differ-
Figure 1 Relation between cardiac index and arterio-venous difference in oxygen content in biguanide-intoxicated patients. Cardiac index 
(CI) and arterio-venous difference in oxygen content [C(a-v)O2] recorded during the first 4 days of admission from 11 biguanide-intoxicated patients. 
Each circle refers to individual data averaged on a daily basis. The arterio-venous difference in oxygen content was computed from either mixed (black 
circles) or central (white circles) venous oxygen saturation. Dotted lines refer to the lower and upper limits of normal systemic oxygen consumption 
(110 to 160 ml/min/m2). Circles that are located under the lower dotted line indicate an arterio-venous difference in oxygen content (oxygen extrac-
tion) lower than expected if systemic oxygen consumption is normal.
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Page 6 of 9ence in O2 content; an inverse correlation was noted
between these variables (R2 = 0.20; P < 0.05, n = 22).
Discussion
The present study demonstrates that whole body O2 con-
sumption (and CO2 production) are abnormally low during
biguanide-induced lactic acidosis and return to normal on
recovery from drug intoxication.
Metformin is a safe drug when correctly prescribed [21].
Lactic acidosis can develop in cases of drug accumulation
but is usually attributed to other concomitant precipitating
factors. However, some reports suggest that metformin
accumulation may cause lactic acidosis even in the absence
of other obvious confounding variables [22]. According to
discharge diagnosis, patients included in this present study
suffered from lactic acidosis (better defined as hyperlac-
tatemia with metabolic acidosis) mainly attributed to (docu-
mented or suspected) metformin or phenformin
intoxication. None of the patients had any sign of acute
liver or cardiac failure. Acute renal failure was invariably
present at hospital admission, but could have hardly repre-
sented the sole cause of such a dramatic rise in blood lactate
levels. Septic shock was never reported as the primary diag-
Figure 2 Relation between systemic oxygen consumption and 
lactatemia in biguanide-intoxicated patients. Systemic oxygen 
consumption (VO2), computed from either mixed (black circles) or cen-
tral (white circles) venous oxygen saturation, inversely correlated with 
plasma lactate (R2 = 0.43; P < 0.001; n = 32).
Table 3: Temporal changes observed in 13 biguanide-intoxicated patients with central venous oxygen saturation (but not 
cardiac index) monitoring
n Day 1 Day 2 Day 3 Day 4 P
pH 13 7.14 ± 0.17 7.36 ± 0.10* 7.45 ± 0.09* 7.43 ± 0.06* <0.001
Lactate (mM) 13 12 ± 6 5 ± 8* 2 ± 1* 2 ± 1* <0.001
C(a-v)O2
(ml O2/100 ml)
12 2.5 ± 1.1 3.1 ± 1.0 3.4 ± 0.8 4.2 ± 1.2* <0.05
SvO2 (%) 12 79 ± 10 75 ± 10 73 ± 6* 66 ± 7* 0.01
OEI (%) 12 20 ± 10 24 ± 10 25 ± 7 33 ± 7* 0.01
C(v-a)CO2
(ml CO2/100 ml)
8 2.4 ± 1.6 2.8 ± 1.2 3.6 ± 0.9 5.5 ± 1.9 0.16
RASS 13 -1 (-4-0) 0 (-3-0) 0 (-1-0) -1 (-3-0) 0.05
On MV (%) 13 31 42 27 38 0.89
HR 12 87 ± 17 88 ± 15 91 ± 14 88 ± 8 0.10
SOFA 13 9 ± 2 8 ± 3 6 ± 3* 7 ± 3* <0.001
Catecholamine 
use (SOFA sub 
score)
13 3 ± 2 3 ± 2 2 ± 2* 2 ± 2* <0.01
BT (°C) 10 35.8
(35.0-36.3)
36.8
(36.4-37.3)
37.0
(36.7-37.5)*
36.9
(36.6-37.4)
<0.05
Results of repeated-measures analysis of variance and chi-squared test are reported in the right column. Data significantly different from day 
1 on post-hoc comparison are indicated as *. n is the number of patients with each specific variable monitored on day 1.
BT, body temperature; C(a-v)O2, arterio-venous difference in oxygen content; C(v-a)CO2, veno-arterial difference in carbon dioxide content; 
HR, heart rate; MV, mechanical ventilation; OEI, oxygen extraction index; RASS, Richmond Agitation Sedation Score; SOFA, Sequential Organ 
Failure Assessment; SvO2, central venous oxygen saturation.
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(gastroenteritis, urinary tract infection) but could not
explain our present initial findings. Indeed, systemic O2
consumption is usually normal or even increased in criti-
cally ill septic patients, at least in the early phase [23,24].
The most common cause of lactic acidosis in critically ill
patients is probably cellular hypoxia. When O2 delivery
acutely decreases due to low cardiac output, anemia or
hypoxemia, tissue O2 extraction rises in an attempt to pre-
serve aerobic mitochondrial respiration. The arterio-venous
difference in O2 content, that is the ratio between whole
body O2 consumption and cardiac output, increases and
central venous O2 saturation decreases. Oxygen consump-
tion only starts to diminish when O2 delivery falls below a
critical value; the blood lactate concentration then abruptly
increases, indicating the development of anaerobic metabo-
lism [25]. The veno-arterial difference in CO2 content, that
depends on the ratio between CO2 production and cardiac
output, may rise as well, mainly as a consequence of a
reduced cardiac output.
Lactic acidosis can also develop under aerobic condi-
tions, when O2 utilization is prevented by mitochondrial
dysfunction, glycolysis is overly stimulated or lactate clear-
ance is impaired [26-28]. Growing evidence, mainly
derived from cell and animal studies, suggest that met-
formin and phenformin can actually interfere with mito-
chondrial respiration in a dose-dependent manner [10,12-
14]. By interfering with mitochondrial respiration in the
liver, they decrease gluconeogenesis (and lactate clearance)
and may potentially increase glucose consumption (and lac-
tate production) [10,12,13]. Although the effect on organs
and tissues other than the liver is less clear, metformin can
still diminish mitochondrial respiration and increase glycol-
ysis (and lactate release) in the skeletal muscle [14].
Whether the drug can decrease global O2 consumption in
either animals or humans remains poorly investigated and
unclear [29-31]. Based on these observations, we hypothe-
size that during metformin or phenformin accumulation, the
inhibition of mitochondrial respiration is so strong that the
production of lactate (by the liver and, probably, other tis-
sues) increases above the residual capacity of the body to
clear it, leading to the development of lactic acidosis.
Our results support this hypothesis. In fact, systemic O2
consumption, measured in 11 patients, was markedly
depressed in the early phase, when lactic acidosis was more
dramatic, despite a normal, or even increased, O2 delivery.
This finding may be cautiously extended to 13 additional
patients in whom systemic O2 consumption could not be
computed, from initial recording of very low values of arte-
rio-venous difference in O2 content, diminished peripheral
O2 extraction and increased central venous O2 saturation.
Similar changes occur after exposure to cyanide, a well-
known inhibitor of mitochondrial respiration [32]. Even if
acidosis was more likely the result of a diminished mito-
chondrial respiration, it might have also contributed to fur-
ther decrease the systemic energy expenditure and O2
consumption [33]. However, the basal systemic O2 con-
sumption of 15 critically ill, mechanically ventilated
patients enrolled in a previous trial led by our group, with
an arterial pH below 7.20, was 123 ± 65 ml/min/m2 [34].
Alterations in O2 consumption were apparently paralleled
by changes in CO2 production. Direct measurement of sys-
temic CO2 production using the reverse Fick equation
requires calculation of the whole blood veno-arterial differ-
ence in CO2 content. This primarily consists of physically
dissolved CO2, bicarbonate ions and carbamino com-
pounds. As whole blood CO2 content is not routinely mea-
sured, we computed it using an algorithm that includes the
CO2 tension, pH, hemoglobin concentration and O2 satura-
tion [17]. Similar to arterio-venous difference in O2 content,
the initially low difference between venous and arterial CO2
content is suggestive of diminished CO2 production.
Previous studies have demonstrated that severity of ill-
ness, use of sedatives and catecholamines, heart rate, body
temperature and mechanical ventilation can all affect rest-
ing energy expenditure [35,36]. Overall, systemic O2 con-
sumption, arterio-venous difference in O2 content and veno-
arterial difference in CO2 content reached their nadir when
severity of illness and use of catecholamines were at their
highest values. Patient awakening occurred slowly, well
after the normalization of O2 consumption and related vari-
ables. Heart rate and the need for mechanical ventilation
did not significantly change over time. A body temperature
on hospital admission averaging 34 to 35°C cannot, in iso-
lation, explain the observed 40 to 60% reduction in sys-
temic O2 consumption, because O2 consumption should
diminish by approximately 5 to 6% for every 1°C fall in
temperature [37,38]. Moreover, the systemic O2 consump-
tion of 25 critically ill patients, with a body temperature
between 34 to 35°C, was 136 ± 40 ml/min/m2 [34]. None of
the patients included in the present study had any obvious
reason to be hypothermic on hospital admission: they usu-
ally arrived from home, were awake and with pale, cold
extremities. Hypothermia was more likely the consequence
of the biguanide-induced decrease in metabolic rate. Even
if abnormally low body temperature may impact upon the
interpretation of the blood gas analyses performed at 37°C,
temperature correction is unnecessary to compute the arte-
rio-venous differences in O2 and CO2 content [39].
Some of the limitations of this present study deserve a
comment. First, we did not include any control group,
because of the peculiar characteristics of the study popula-
tion. However, every single patient with biguanide intoxica-
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Page 8 of 9tion acted as an internal control, with individual recordings
of global O2 consumption (and CO2 production) being sig-
nificantly lower on day 1, relative to the following days.
Second, we used the central venous O2 saturation to com-
pute global O2 consumption of patients equipped with a car-
diac output monitoring but not a pulmonary artery catheter.
As catecholamine use did not change over time in these
subjects, changes in central venous O2 saturation (and
derived variables) likely reflected those in mixed venous O2
saturation. Moreover, when the analysis was restricted to
the 7 patients equipped with a pulmonary artery catheter,
the major findings of the study remained valid. Third, the
respiratory quotient - the ratio between the difference in
CO2 and O2 content of simultaneously drawn arterial and
venous blood samples - sometimes exceeded one, an unex-
pected finding, at least at steady state. Possible explanations
include the fact that, in our study population, blood gas
analysis were not performed at steady state and blood CO2
content was estimated rather than directly measured. We
cannot, however, definitely exclude the occurrence of any
error in blood sampling, gas analysis or data reporting.
Conclusions
Metformin and phenformin intoxication is characterized by
severe lactic acidosis and abnormally low systemic oxygen
consumption despite normal or even increased systemic
oxygen delivery. These findings are consistent with the
hypothesis that biguanide drugs cause lactic acidosis by
inhibiting mitochondrial respiration, without any clear evi-
dence of cellular hypoxia. Cause and effect still needs to be
conclusively demonstrated.
Key messages
• The progressive increase in metformin use may result
in a parallel increase in the incidence of associated lac-
tic acidosis.
• The pathogenesis of biguanide-associated lactic acido-
sis remains unclear, especially when it develops in the
absence of other major risk factors.
• Biguanide intoxication is characterized by severe lac-
tic acidosis and abnormally low systemic O2 consump-
tion, despite normal or even increased global oxygen
delivery.
• Resolution of drug intoxication is paralleled by cor-
rection of lactic acidosis and normalization of systemic
O2 consumption.
• These findings are in line with the hypothesis that lac-
tic acidosis develops during metformin or phenformin
intoxication because of inhibition of mitochondrial res-
piration.
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